Non-Alcoholic Steatohepatitis Treatment Market

The global non-alcoholic steatohepatitis (NASH) treatment market is projected to reach USD 15 billion by 2027 from USD 5 Billion in 2022, at a CAGR of ~25% during the forecast period

To know about the assumptions considered for the study, Request for Free Sample Report

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Chronic inflammation causes progressive liver damage. Major symptoms registered are fatigue (feeling tired all the time), weight loss for no clear reason, general weakness, an ache in the upper right part of your belly. However, increased investment in launch of novel drugs for the treatment of NASH is likely to drive the market growth in coming years. Additionally, rising prevalence of NASH is further anticipated to spur the market growth. For instance, according to American Liver Foundation it’s estimated that about 25 percent of adults in the U.S. have NAFLD. Of those with NAFLD, about 20 percent have NASH (5% of adults in the U.S.). Most people with NAFLD have simply fatty liver.

In non-alcoholic steatohepatitis treatment is segmented by drug class, distribution channel and region. Based on drug class the market is further segmented into Obeticholic Acid (OCA), Vitamin E And Pioglitazone, Lanifibranor, Semaglutide, Cenicriviroc, and Other Products. Among these Vitamin E and pioglitazone segment is likely to dominate market. The domination of off-label therapies can be attributed to the absence of approved therapeutic options in the market. Off-label treatments like Vitamin E are the most prescribed therapeutics for non-alcoholic steatohepatitis.

FDA approvals for NASH drugs is one of the major factor projecting the market growth. In March 2020, The Drug Controller General of India approved Zydus’ saroglitazar for non-cirrhotic non-alcoholic steatohepatitis (NASH), making this the first drug approved for this indication approved anywhere in the world. According to Clinicalgov data around 261 candidates are under clinical trials for NASH, these are expected to be launched during the forecast period.

Based on region, the market is segmented into North America, Europe, Asia Pacific and ROW. Among the region, North America is anticipated held dominant share owing to various factors such as rising prevalence of NASH, increased healthcare expenditure, patient awareness about the diseases and presence of major players in the region.

Major players operating in the market are Astrazeneca Plc (UK), Intercept Pharmaceuticals Inc. (US), Galmed Pharmaceuticals Ltd. (Israel), Genfit Sa (France), Gilead Sciences, Inc. (US) and among others

To know about the assumptions considered for the study, download the pdf brochure

Global Non-Alcoholic Steatohepatitis Treatment Market

The research report categorizes the Non-alcoholic steatohepatitis treatment market into following segments.

Non-Alcoholic Steatohepatitis Treatment Market, By Drug Class

• Obeticholic Acid (OCA)
• Vitamin E And Pioglitazone
• Lanifibranor
• Semaglutide
• Cenicriviroc
• Other Products (If Any)

Non-Alcoholic Steatohepatitis Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Pulmonary Arterial Hypertension Market, By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • ROE
• Asia Pacific
  • Japan
  • China
  • India
  • Rest Of APAC
• Rest Of the World (Row)

To speak to our analyst for a discussion on the above findings, click Speak to Analyst